Biden proposal targeting pharma patents spurs industry fears and consumer doubts; FDA, PTO seek to work together to lower drug prices

Taking stock of the drug industry, from the lab to the medicine chest

December 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Biden proposal targeting pharma patents spurs industry fears and consumer doubts "This is going to be a long process, but there will be a lot of debate because there is a lot at stake," said Harvard's Aaron Kesselheim. By Ed Silverman STAT+ | 'Learning each other's language': FDA, patent office seek to work together to lower drug prices Following an executive order, the two agencies have been trying to collaborate, but it's been a challenging, time-consuming process. By Ed Silverman STAT+ | Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it? Sanofi also said that it would increase the number of Phase 3 studies it is conducting by 50% between 2023 and 2025. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser